Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $95

Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $110 to $95.